Company / Capital Expenditures
Caris Life Sciences, Inc. Capital Expenditures History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$16.3M
FY2025
5-year range
$8.4M / $22.3M
FY2023-FY2025
Trend
+92.6%
vs FY2024
Sector context
#107 of 150
Health Care
What the data says
At $16M, Caris Life Sciences, Inc.'s capital expenditures ranks #107 of 150 in the Health Care sector. Declined from $22M to $16M over the past 2 years.
Based on SEC 10-K filings.
$16M in FY2025.
Declined from $22M to $16M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 150 in Health CareTop 71% of 150This company $16.3M Sector average $271.1M
▼
-94.0% below sector average
Key checks
Key Insights
- In FY2025, capital expenditures increased 92.6% year-over-year.
- Ranks #107 out of 150 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.3M | +92.6% |
| FY2024 | $8.4M | -62.2% |
| FY2023 | $22.3M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026